醋酸格拉替雷孕期及哺乳期暴露的妊娠、胎儿和婴儿结局
基于Teva药物警戒数据库2019至2021年前瞻性妊娠报告,评估醋酸格拉替雷20和40 mg/mL暴露后妊娠、胎儿及婴儿结局。702例已知结局胎儿中活产647例(92.2%),主要先天畸形率1.1%、早产率7.2%、低/极低出生体重率4.8%,均处于背景水平,未报告婴儿发育迟缓。
要点
- 醋酸格拉替雷孕期暴露后主要先天畸形率1.1%,处于背景水平。
- 活产率92.2%,自发流产率6.7%,早产率7.2%,低/极低出生体重率4.8%。
- 20 mg/mL与40 mg/mL剂量间妊娠及婴儿结局相似。
核心结论
- 母体孕期暴露于醋酸格拉替雷似乎与不良妊娠、胎儿或婴儿结局无关。
- 数据进一步支持醋酸格拉替雷20 mg/mL和40 mg/mL在孕期和哺乳期使用的安全性。
研究设计与样本
- 从Teva药物警戒数据库提取2019至2021年醋酸格拉替雷宫内暴露的上市后妊娠报告。
- 使用前瞻性报告(在知晓妊娠结局或检测到先天畸形之前获取)估算妊娠和婴儿结局率。
- 部分病例完成随访问卷并单独分析。
主要发现
- 702例已知结局胎儿中活产647例(92.2%)、自发流产47例(6.7%)、人工流产4例(0.6%)、异位妊娠2例(0.3%)、胎儿死亡2例(0.3%)。
- 主要先天畸形率1.1%、早产率7.2%、低/极低出生体重率4.8%及生长参数均在背景率范围内。
- 未报告婴儿发育迟缓。
- 醋酸格拉替雷不同剂量间妊娠和婴儿结局总体相似。
关键数值与推荐
- 主要先天畸形率1.1%(前瞻性已知结局胎儿)。
- 早产率7.2%(前瞻性已知结局胎儿)。
- 低/极低出生体重率4.8%(前瞻性已知结局胎儿)。
- 活产率92.2%、自发流产率6.7%(前瞻性已知结局胎儿)。
临床怎么用
- 临床可参考这些数据支持醋酸格拉替雷20 mg/mL和40 mg/mL在孕期和哺乳期使用的安全性。
- 咨询时应告知主要先天畸形率1.1%、早产率7.2%等数值处于背景水平。
局限性
- 长期数据有限。
- 数据来源于上市后妊娠报告,可能存在报告偏倚。
- 仅部分病例完成随访问卷并单独分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Published data support the safety of glatiramer acetate in patients with multiple sclerosis who are pregnant or breastfeeding, but long-term data are limited. OBJECTIVE: We aimed to assess pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate. METHODS: In-utero glatiramer acetate-exposed postmarketing pregnancy reports from 2019 to 2021 were extracted from Teva's pharmacovigilance database. Pregnancy data acquired prior to knowledge of pregnancy outcome or detection of congenital malformation (prospective reports) were used to estimate pregnancy and infant outcome rates for glatiramer acetate 20- and 40-mg/mL exposure. A subgroup of cases completed follow-up questionnaires and were analyzed separately. RESULTS: Prospective cases with 702 fetuses had known outcomes with 647 (92.2%) live births, 47 (6.7%) spontaneous abortions, 4 (0.6%) induced abortions, 2 (0.3%) ectopic pregnancies, and 2 (0.3%) fetal deaths. Rates of major congenital malformation (1.1%), preterm births (7.2%), and low/very low birth weight (4.8%), and parameters of growth were within background rates. No infant developmental delay was reported. Overall, pregnancy and infant outcomes were similar across glatiramer acetate doses. CONCLUSIONS: Maternal exposure to glatiramer acetate does not appear to be related to adverse pregnancy, fetal, or infant outcomes. These data further support the safety of both glatiramer acetate 20-mg/mL and 40-mg/mL treatments during pregnancy and breastfeeding.
引用
- Kaplan S, Zeygarnik M, Stern T, et al. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. Drug Saf. 2022. PMID: 35297004. doi:10.1007/s40264-022-01168-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。